The increasing problem of hepatitis C virus infection

Australian Dental Journal

Volumn 46, Issue 1, 2001, Pages 13-17

  Coates, E A ^a   Walsh, L ^b   Logan, R ^c  

^a Adelaide Dental Hospital   (Australia)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

Dental pathology; Hepatitis C; Oral health; Preventive programs

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; VIRUS RNA;

AUSTRALIA; DENTAL CARE; DISEASE TRANSMISSION; HEPATITIS C; HUMAN; INCIDENCE; INFECTION CONTROL; REVIEW; RISK FACTOR;

ANTIVIRAL AGENTS; AUSTRALIA; DENTAL CARE FOR CHRONICALLY ILL; DISEASE TRANSMISSION; HEPATITIS C; HUMANS; INCIDENCE; INFECTION CONTROL, DENTAL; INTERFERON ALFA-2B; RISK FACTORS; RNA, VIRAL;

EID: 0042235145     PISSN: 00450421     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1834-7819.2001.tb00268.x     Document Type: Review

References (32)

1. First Australian Conference on Hepatitis C. Conference Proceedings, Sydney 1997.
2. HIV and related diseases in Australia. Annual Surveillance Report, National Centre in HIV Epidemiology and Clinical Research 1998.
3. Farrell G. Chronic viral hepatitis. Med JAust 1998;168:619-626.
4. Alter MJ, Mast EE, Moyer LA, Margolis HS. Hepatitis C. Infect Dis Clin North Am 1998;12:13-26.
5. Molinari JA. Hepatitis C virus infection. Dent Clin North Am 1996;40:309-325.
6. Roffi L, Ricci A, Ogliari C, et al. HCV genotypes in Northern Italy: a survey of 1368 histologically proven chronic hepatitis C patients. J Hepatol 1998;29:701-706.
7. Chen M, Sallberg M, Sonnerborg A, et al. Limited humoral immunity in hepatitis C virus infection. Gastroenterology 1999;116:135-143.
8. Thomson JA, Rodger AJ, Thompson SC, et al. The prevalence of hepatitis C in patients admitted with acute hepatitis to Fairfield Infectious Diseases Hospital 1971-1975. Med J Aust 1998;169:360-363.
9. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-1432.
10. Guido M, Rugge M, Jara P, et al. Chronic hepatitis C in children: the pathological and clinical spectrum. Gastroenterology 1998;115:1525-1529.
11. Bonkovsky HL, Woolley JM. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology 1999;29:264-270.
12. Farrell G. Interferon treatment for chronic viral hepatitis in Australia: is it worth it? Med J Aust 1992;156:873-875.
13. Del Pozo MA, Arias JR, Pinilla J, et al. Interferon alpha treatment of chronic hepatitis C in HIV-infected patients receiving zidovudine: efficacy, tolerance and response related factors. Hepato-Gastroenterology 1998;45:1695-1701.
14. Whyte GS, Savoia HF. The risk of transmitting HCV, HBV or HIV by blood transfusion in Victoria. Med J Aust 1997;166:584-586.
15. Heintges T, Mohr L, Niederau C, et al. Quantitative hepatitis C RNA-polymerase chain reaction and detection with DNA-ELISA. Hepatogastroenterology 1998;45:1684-1689.
16. Alter MJ, Moyer LA. The importance of preventing hepatitis C virus infection among injection drug users in the United States. J Acquir Immune Defic Syndr Hum Retrovirol 1998;18(Suppl 1):S6-10.
17. Flamm SI, Parker R, Chopra S. Risk factors associated with chronic hepatitis C virus infection: limited frequency of an unidentified source of transmission. Am J Gastroenterol 1998;93:597-600.
18. Crofts N, Aitken CK, Kaldor JM. The force of numbers: why hepatitis C is spreading among Australian injecting drug users while HIV is not. Med J Aust 1999;170:220-221.
19. Lin R, Dutta U, Kaba S, et al. Effects of hepatitis G virus coinfection on severity of hepatitis C: Relationship to risk factors and response to interferon treatment. J Gastroenterol Hepatol 1998;13:773-780.
20. Chen M, Yun ZB, Sallberg M, et al. Detection of hepatitis C virus RNA in the cell fraction of saliva before and after oral surgery. J Med Virol 1995;45:223-226.
21. Porter SR, Lodi G. Hepatitis C virus (HCV) - an occupational risk to dentists? Br Dent J 1996;180:473-474.
22. Fagan EA, Partridge M, Sowray JH, Williams R. Review of hepatitis non-A, non-B: the potential hazards in dental care. Oral Surg Oral Med Oral Pathol 1988;65:167-171.
23. Epstein JB, Sherlock CH. Hepatitis C: rapid progress in medicine and implications for dentistry. J Can Dent Assoc 1994;60:323-329.
24. Thomas DI, Gruninger SE, Siew C, et al. Occupational risk of hepatitis C infections among general dentists and oral surgeons in North America. Am J Med 1996;100:41-45.
25. Dreyer AF, Aspinall S, Jacobs FJ. Prevalence of markers for human immunodeficiency, hepatitis B and hepatitis C viruses in maxillofacial and oral surgery patients at Medunsa. J Dent Assoc S Afr 1993;48:377-380.
26. Epstein JB, Porter SR, Scully C. Non-A, non-B hepatitis and dentistry: a status report for the American Journal of Dentistry. Am J Dent 1992;5:49-55.
27. Piazza M, Borgia G, Picciotto L, et al. Detection of hepatitis C virus-RNA by polymerase chain reaction in dental surgeries. J Med Virol 1995;45:40-42.
28. Wisnom CJ, Kelly M. Medical/dental management of a chronic hepatitis C patient. Oral Surg Oral Med Oral Pathol 1993;75:786-790.
29. Weiss K. Hepatitis C: what a dentist should know. J Can Dent Assoc 1995;61:537-540.
30. Coates EA, Brennan D, Logan RM, et al. Hepatitis C infection and associated oral health problems. Aust Dent J 2000;45:108-114.
31. Carrozzo M, Gandolfo S, Lodi G, et al. Oral lichen planus in patients infected or noninfected with hepatitis C virus: the role of autoimmunity. J Oral Pathol Med 1999;28:16-19.
32. Gorksy M, Raviv M, Moskona D, et al. Clinical characteristics and treatment of patients with oral lichen planus in Israel. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996;82:644-649.